Does Medicare Cover Dupixent?

Dupixent has quietly become one of the most prescribed biologics in the country, because it treats a remarkable range of conditions driven by the same underlying type of inflammation — severe eczema, asthma, COPD, chronic sinus disease with nasal polyps, and several others. For the Medicare population, that breadth means a lot of beneficiaries end up with a Dupixent prescription, and a lot of them have the same first reaction when they see the price: this can’t possibly be covered.

It is covered. The reassurance most patients need is that, despite a wholesale price near $3,800 a month, what you actually pay on Medicare in 2026 is capped — and the cap changed the math dramatically compared to just two years ago.

What Dupixent treats

Dupixent (dupilumab) is an injectable biologic that blocks part of the immune system’s inflammatory signaling (the IL-4 and IL-13 pathways). Its FDA-approved uses include:

• Moderate-to-severe atopic dermatitis (eczema)
• Moderate-to-severe asthma (eosinophilic or oral-steroid-dependent)
• COPD with an eosinophilic phenotype
• Chronic rhinosinusitis with nasal polyps
• Eosinophilic esophagitis
• Prurigo nodularis

When prescribed for any of these approved conditions, Medicare Part D covers it. The COPD approval in particular is significant for the Medicare population, since COPD is so common in older adults.

How Medicare covers it — and why it’s Part D

Dupixent is a self-administered injection — you (or a caregiver) inject it under the skin at home, typically every two weeks. Because you administer it yourself rather than receiving it in a clinic, it falls under the Part D prescription drug benefit, not Part B.

That distinction matters in your favor. Part D drugs are subject to the $2,000 annual out-of-pocket cap that took effect in 2025 — so no matter how expensive Dupixent’s list price is, your total yearly out-of-pocket for covered Part D drugs can’t exceed $2,000. (Part B drugs, by contrast, have no such cap.)

You fill Dupixent through a pharmacy, usually a specialty pharmacy that handles refrigerated biologics and coordinates with your plan.

What you’ll actually pay

Dupixent sits on the specialty tier (Tier 5) of essentially every Part D formulary, which means coinsurance (a percentage of the price) rather than a flat copay — typically 25–33%.

Here’s how a year plays out in 2026:

• Early in the year: You pay the deductible (if your plan has one, up to $590) plus specialty coinsurance on your first fills. With Dupixent’s price, this is a large number fast — often $1,500–$2,000 in the first month or two.
• After you hit $2,000: You pay $0 for the rest of the calendar year on covered Part D drugs.
• The counter resets January 1.

So your realistic annual out-of-pocket for Dupixent is about $2,000, concentrated in the first part of the year. Compared to the old Part D structure — where specialty drug users routinely paid $5,000–$10,000+ per year — this is a major improvement.

One more tool: the Medicare Prescription Payment Plan (launched 2025) lets you spread that $2,000 across monthly installments instead of paying it all up front in January. For a drug like Dupixent where costs front-load hard, this is genuinely useful — ask your plan to enroll you.

And if your income is limited, Extra Help (the Part D Low-Income Subsidy) can reduce your costs further, sometimes to just a few dollars per fill.

Prior authorization and step therapy

Expect hoops. As a high-cost biologic, Dupixent triggers:

• Prior authorization on virtually every plan — your prescriber submits documentation of your diagnosis and its severity.
• Step therapy on many plans — you may need to show you’ve tried and failed (or can’t tolerate) less expensive treatments first. For eczema, that often means topical therapies; for asthma, inhaled controller medications.

The practical key is documentation. Patients moving to Medicare from commercial insurance sometimes hit a wall because the new plan can’t see their treatment history. Ask your specialist’s office to prepare a summary of what you’ve tried and how your condition has responded — that summary is the backbone of the prior authorization, and it’s also what wins appeals if the first request is denied. Part D denials are reversed at meaningful rates when the clinical case is solid, so don’t take an initial “no” as final.

No manufacturer copay card — but other help exists

A common and costly assumption: that you can use the Dupixent MyWay copay card to bring your cost down. You can’t. Federal law prohibits using manufacturer copay assistance with Medicare Part D, and the card explicitly excludes people with government insurance.

On Medicare, your cost relief comes from:

• The $2,000 annual cap
• The Prescription Payment Plan to spread it out
• Extra Help, if you qualify by income

These replace the manufacturer card, and for most beneficiaries the $2,000 cap is more valuable than the card would have been over a full year anyway.

Where Dupixent fits among the specialty drugs

Dupixent is one of several specialty biologics the Medicare population commonly uses, and they all follow the same pattern — specialty tier, prior authorization, front-loaded cost, $2,000 cap. If you’re also looking at psoriasis biologics like Otezla or Tremfya, or a COPD inhaler like Trelegy, the cost mechanics will feel familiar. The good news is that the annual cap applies across all your Part D drugs combined — so even if you take more than one specialty medication, your total Part D out-of-pocket is still capped at $2,000 for the year.

Bottom line

Medicare Part D covers Dupixent for all its approved conditions, including the COPD and asthma uses that matter most to older adults. Yes, it’s a specialty-tier drug with prior authorization and a high list price — but the $2,000 annual out-of-pocket cap means your real cost is bounded and predictable, and the Prescription Payment Plan lets you spread it across the year. Confirm your plan’s prior authorization requirements before your first fill, have your prescriber document your treatment history, and the path to coverage is straightforward.